GlobeNewswire by notified

Fujifilm launches a more comprehensive portfolio for Europe's healthcare community following the integration of Hitachi Diagnostic Imaging

Share

Düsseldorf, July 01, 2021 (GLOBE NEWSWIRE) -- Today at a virtual European event, the newly named FUJIFILM Healthcare Europe and FUJIFILM Europe’s existing European medical business (hereinafter referred to as “Fujifilm”) presented a complete and integrated portfolio of diagnostic products and services, including CT, MRI, X-ray, AI, PACS, endoscopy and ultrasound systems. Today's launch follows the completion of Fujifilm's acquisition and takeover of Hitachi's Diagnostic Imaging-related business on 31 March 2021 for 179 billion yen (€1.3 billion), with the newly named FUJIFILM Healthcare Europe also launching today.

Presenting a more comprehensive portfolio to an audience of key opinion leaders in the medical community, customers and the media, the synergy of FUJIFILM Healthcare Europe and Fujifilm is central to the growth strategy of the Japanese multinational in Europe, as Fujifilm looks to establish itself as a healthcare market leader. Combining the two organisations’ product line-ups enhances Fujifilm's overall capability to offer a comprehensive solution that caters to a broad range of clinical needs.

As a result of this strengthened offer, Fujifilm intends to significantly expand its diagnostics business globally as one of the Group's leading growth drivers, aiming to achieve a turnover of 860 billion yen (€6.6 billion) within the next three years; a growth of more than 50% compared to the fiscal year ending March 2020.

Today's virtual event presented the European medical community with a comprehensive healthcare portfolio. FUJIFILM Healthcare Europe's expertise in CT, MRI and ultrasound, combined with Fujifilm’s business’ core capabilities in x-ray, endoscopy, women's health, AI, PACS and IVD, allow the company to maximise its services and products in several areas of prevention and diagnosis for the benefit of patients in Europe.

Highlights of the enhanced portfolio that demonstrate this new strength include:

1)   FUJIFILM Healthcare Europe's high-image-quality and robust CT combined with Fujifilm’s AI technology platform REiLI, and SYNAPSE 3D, which supports post-processing, offering a low dose solution to radiology departments and total support from imaging to diagnosis.

2)   An enhanced Fujifilm offering to a wider range of hospital departments, including gynaecology, surgery and urology. For example, the clinical application of FUJIFILM Healthcare Europe's ultrasound technology in surgery provides a platform for Fujifilm’s new introduction of surgical endoscopes and SYNAPSE 3D.

3)   Expanded application and technical support and service across the complete portfolio of Fujifilm medical products.

"We have worked hard to achieve this important milestone for Fujifilm and its future development. Today we are stronger together, and our goal is to maximise these new comprehensive and complete portfolio synergies. Our goal is to position ourselves as a market leader and number one comprehensive partner for the Healthcare community in Europe in the field of prevention and diagnosis," says Toshi Iida, President and Managing Director of FUJIFILM Europe.

"Thanks to this important acquisition, we have combined the strengths and skills of two leading companies in the sector, and today we offer a package of comprehensive and cutting-edge solutions. Fujifilm is now a company that offers a more comprehensive portfolio to healthcare providers across Europe. New milestones await us in AI, Healthcare IT, CT, MRI, ultrasound and many more fields, intending to create new values of excellence across this exciting new combined team," adds Masaharu Fukumoto, Senior Vice President, FUJIFILM Europe.

"We bring to Fujifilm many decades of experience in the market, alongside a strong and comprehensive product portfolio. The two organisations complement each other perfectly, and I am excited for the service and support we can offer together with a new combined team that is ready to embrace new challenges and great adventures in the future. Together we are stronger," said Jean-Luc Budillon, President and COO, FUJIFILM Healthcare Europe.

About Fujifilm in Europe
Fujifilm operates over 50 group companies and branches in Europe and employs approximately 4,500 people engaged in R&D, manufacturing, sales and service, with FUJIFILM Europe GmbH, located in Düsseldorf, Germany, operating as the strategic headquarters for the region. Throughout Europe, Fujifilm entities serve a range of industries including medical technology, biopharmaceuticals, electronic materials, industrial products, chemicals, graphic systems, optical devices, data storage and all aspects of photography. Over the last 20 years, the company has more intensively focused on healthcare - from diagnosis to prevention and treatment. Today, Fujifilm in Europe provides the entire spectrum of patient care, in addition to research, development and manufacturing in advanced therapies, gene therapies and vaccines, as well as providing cell culture media and regenerative medicine solutions.
For more information, please visit: fujifilm.com

About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, located in Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the fiscal year ended March 31, 2021, the company had global revenues of Euro 16,7 billion, at an exchange rate of 131,6 yen to the Euro. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.
For more information, please visit: holdings.fujifilm.com

Contact information:
Luana Porfido
Head of Corporate Communications – Europe
FUJIFILM Europe GmbH
luana.porfido@fujifilm.com
+39 (0)3459529101

Andy Ross
Deputy Head of Corporate Communications – Europe
FUJIFILM Europe GmbH
andy.jm.ross@fujifilm.com
+44 (0)7766497949

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Siili Solutions Plc: Business review, 1 January–31 March 202424.4.2024 08:45:00 CEST | Press release

Siili Solutions Plc: Business review, 1 January–31 March 2024 Siili’s result decreased as expected, good development within AI Siili Solutions Plc Stock Exchange Release 24 April 2024 at 9:45 am EEST Key figures EUR millionQ1/2024Q1/2023Revenue29.833.6Revenue growth, EUR million-3.84.3Revenue growth, %-11.3%14.5%Organic revenue growth, EUR million-3.82.7Organic revenue growth, %-11.3%8.6%Adjusted EBITA11.63.3Adjusted EBITA, % of revenue5.3%10.0%EBITA1.43.3EBITA, % of revenue4.6%10.0%Average number of employees during the period9901,050Number of employees at the end of the period9731,054Number of full-time employees (FTE) at the end of the period9501,024Number of full-time subcontractors (FTE) at the end of the period2137187 1EBITA adjustments EUR 0.2 million consisted of personnel expenses related to restructuring of operations.2The figure for the comparison period has been retroactively corrected. Key events in January-March: Siili streamlined its organisational structure and COO Kari

Scatec signs PPA with Statkraft for new 142 MW solar plant in Brazil24.4.2024 08:45:00 CEST | Press release

Oslo, 24 April 2024: Scatec ASA, a leading renewable energy solutions provider, signed a 10-year power purchase agreement (PPA) with Statkraft Energia do Brasil Ltda in Brazil, for a 142 megawatt (MW) solar plant in Minas Gerais, in Brazil. The BRL-denominated PPA covers about 75% of the expected power produced, while the remainder is expected to be sold under short, medium, and long-term term contracts (PPAs). The project’s estimated equity return exceeds Scatec’s hurdle rate of 1.2x the project’s cost of equity. The estimated total capital expenditure (capex) for the solar plant is USD 94 million, to be financed by non-recourse financing covering approximately 63% of this amount with the balance funded by equity from Scatec. Furthermore, Scatec is in mature discussions with lenders in respect of a debt facility of approximately EUR 15 million to partially fund Scatec’s equity share in the project. Financial close and construction start for the solar plant is expected in the second ha

Opjustering af forventninger til årets resultat 2024.24.4.2024 08:32:34 CEST | pressemeddelelse

Nasdaq Copenhagen Silkeborg, den 24. april 2024 Fondsbørsmeddelelse nr. 5 / 2024 Vedr.: Opjustering af forventninger til årets resultat 2024. Den forretningsmæssige udvikling i selskabets fodbold-segment udvikler sig bedre end forventet, hvilket medfører at selskabets resultatforventning i dette regnskabsår opjusteres til et resultat før evt. dagsværdiregulering af investeringsejendomme og før skat i intervallet +12 mio. kr. til +20 mio. kr., mod tidligere et resultat i intervallet +7 mio. kr. til +15 mio. kr. Med venlig hilsen Silkeborg IF Invest A/S Kent V. Madsen Claus Christensen Adm. direktør Økonomidirektør Vedhæftet fil 5. Opjustering af forventninger til årets resultat (20240424)

Danske Bank A/S, ledende medarbejderes transaktioner24.4.2024 08:30:54 CEST | pressemeddelelse

24. april 2024 Indberetning nr. 42/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024.04.23

Danske Bank A/S, transactions by persons discharging managerial responsibilities24.4.2024 08:30:54 CEST | Press release

24 April 2024 Notification no. 42/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024.04.23

HiddenA line styled icon from Orion Icon Library.Eye